idarubicin ( idr ) is a new analog of daunorubicin ( dnr ) selected for clinical trials because of its outstanding activity in experimental leukemias of mice and in several experimental models when compared to dnr and doxorubicin .
C0011015
dnr
C0013089
doxorubicin